Abstract:
Structurally novel kappa opioid receptor antagonists are provided and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.
Abstract:
Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors relative to nor-BNI, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.
Abstract:
The present application relates to novel opioid receptor antagonists and agonists, methods of making these compounds, and methods of use thereof.
Abstract:
The present application relates to novel opioid receptor antagonists and agonists, methods of making these compounds, and methods of use thereof.
Abstract:
The present invention relates to a class of nitrogen-containing heterocyclic compounds which bind to opioid receptors. The inventive compounds can be used to treat a variety of disease states which involve the opioid receptors.
Abstract:
The present application relates to novel opioid receptor antagonists and agonists, methods of making these compounds, and methods of use thereof.
Abstract:
The present application relates to novel opioid receptor antagonists and agonists, methods of making these compounds, and methods of use thereof.